Livagen – 20MG

Scientific Overview of Livagen

Livagen is a short-chain peptide bioregulator that has drawn attention in research due to its potential interactions with genetic and cellular processes. Classified among Khavinson’s peptides, Livagen is often compared to Epitalon, as both are associated with studies on chromatin remodeling and gene regulation. The peptide has been explored in relation to lymphocytes, liver cells, and the gastrointestinal system, where it may participate in modulating cellular organization and communication pathways.

One of the central research interests surrounding Livagen involves its potential role in altering chromatin states, which may influence gene accessibility and transcriptional activity. By appearing to modify how tightly DNA is packaged, the peptide may provide conditions for the activation of previously silent genes. This possibility has led to experimental exploration of Livagen in the context of cellular aging, immune system regulation, and tissue-specific processes.

In addition, Livagen has been investigated as part of broader research on peptides that might affect inflammation, oxidative balance, and cellular repair systems. While the outcomes remain exploratory, such lines of inquiry suggest that Livagen could represent a model peptide for studying the interface between genetic material and environmental or age-related factors.

Alternative Names: SCHEMBL5967826

Livagen Studies and Research Data

Chromatin Organization and Gene Accessibility

Research suggests that Livagen may influence chromatin compaction, especially in lymphocytes, where nucleolar organizer regions (NORs) play an important role in ribosomal RNA synthesis. Studies propose that the peptide could alter how acrocentric chromosomes associate, potentially through decondensation of heterochromatin. Such activity might open access to genes that are otherwise silenced, thereby supporting different transcriptional patterns within cells.

Lymphocytes and Immune Regulation

Several investigations indicate that Livagen may activate silent genes within lymphocytes by influencing chromatin structure. This process could be linked to ribosomal gene activity and subsequent protein synthesis. In experimental models, long-term exposure to Livagen appeared to induce lymphocyte behavior that resembled patterns observed in younger counterparts. Researchers have suggested that this may reflect renewed activity of T and B cells, which are essential for immunological defense and signaling.

Cellular Aging and Chromosomal Stability

As chromatin condensation and DNA repair mechanisms change with age, some studies have looked at Livagen as a potential factor in mitigating these alterations. Experimental evidence points to the possibility that Livagen, along with related peptides, may assist in decondensing DNA, thereby supporting cell viability in laboratory models. This line of research is especially focused on the ways in which chromosomal aberrations accumulate over time and how certain peptides may influence these processes.

Livagen and Cardiac Research Models

Livagen has also been examined in relation to cardiac cells, particularly through its interactions with lymphocytes and their gene expression. In models of hypertrophic cardiomyopathy, the peptide has been associated with changes in chromatin dynamics that could influence inflammation and tissue responses. One study described Livagen, sometimes tested alongside cobalt ions, as contributing to normalization of altered genomic patterns in conditions linked to atherosclerosis.

Livagen and Gastrointestinal Pathways

Preliminary research suggests that Livagen may influence gastrointestinal processes, possibly through vagus nerve signaling and modulation of prostaglandins and nitric oxide levels. These mechanisms are thought to contribute to protective responses in the mucosal wall of the gastrointestinal tract, making Livagen of interest in models related to inflammation and digestive function.

Pain Signaling and Enkephalin Activity

Another focus of research has been Livagen’s relationship to enkephalins, peptides involved in natural pain regulation. Studies suggest that Livagen may reduce the breakdown of enkephalin molecules by inhibiting enzymes in the bloodstream. Rather than interacting with opioid receptors directly, Livagen appears to influence the persistence of enkephalins, thereby potentially enhancing endogenous pathways of pain modulation.

Livagen and Oxidative Balance in Liver Models

Investigations into liver pathology have explored Livagen for its possible antioxidant properties. In in vitro models simulating fibrosis and hepatitis, the peptide was reported to normalize oxidative status. Researchers propose that this action could be relevant in studies of cellular aging, as oxidative stress is often implicated in reduced cellular function.

Conclusion

Livagen is studied as a peptide bioregulator with potential connections to chromatin remodeling, gene expression, and cellular stability. Research has considered its roles in lymphocytes, gastrointestinal pathways, liver systems, and even cardiac models, where it may contribute to broader understanding of genetic and cellular interactions. While these studies remain exploratory, they collectively highlight Livagen as a point of interest in ongoing investigations into peptides and gene regulation.

References

1. Kuznik BI, Khasanova NB, Ryzhak GA, Mezsheriakova IE, Khavinson VK. [The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology.]. Adv Gerontol. 2020;33(1):159-164. Russian. PMID: 32362099.
2. Khavinson, V. K.h, Lezhava, T. A., Monaselidze, J. G., Dzhokhadze, T. A., Dvalishvili, N. A., Bablishvili, N. K., & Ryadnova, I. Y. (2002). Effects of Livagen peptide on chromatin activation in lymphocytes from old people. Bulletin of experimental biology and medicine, 134(4), 389–392. https://doi.org/10.1023/a:1021924702103
3. Gyires, K., & Rónai, A. Z. (2001). Supraspinal delta- and mu-opioid receptors mediate gastric mucosal protection in the rat. The Journal of pharmacology and experimental therapeutics, 297(3), 1010–1015.
4. Lezhava, T. A. (2001). Funktsional’nye osobennosti khromosom cheloveka i starenie [Human chromosome functional characteristics and aging]. Advances in gerontology = Uspekhi gerontologii, 8, 34–43.
5. Khavinson, V. K.h, Lezhava, T. A., Monaselidze, J. R., Jokhadze, T. A., Dvalishvili, N. A., Bablishvili, N. K., & Trofimova, S. V. (2003). Peptide Epitalon activates chromatin at the old age. Neuro endocrinology letters, 24(5), 329–333.
6. Dzhokhadze, T. A., Buadze, T. Z.h, Gaiozishvili, M. N., Kakauridze, N. G., & Lezhava, T. A. (2014). Georgian medical news, (236), 82–86.
7. van Steensel B. (2011). Chromatin: constructing the big picture. The EMBO journal, 30(10), 1885–1895. https://doi.org/10.1038/emboj.2011.135
8. Lezhava, T., & Jokhadze, T. (2007). Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals. Annals of the New York Academy of Sciences, 1100, 387–399. https://doi.org/10.1196/annals.1395.043
9. Kost, N. V., Sokolov, O. I.u, Gabaeva, M. V., Zolotarev, I.uA., Malinin, V. V., & Khavinson, V. K.h (2003). Effect of new peptide bioregulators Livagen and Epitalon on enkephalin-degrading enzymes in human serum. Izvestiia Akademii nauk. Seriia biologicheskaia, (4), 427–429.
10. Lezhava, T., Monaselidze, J., Kadotani, T., Dvalishvili, N., & Buadze, T. (2006). Anti-aging peptide bioregulators induce reactivation of chromatin. Georgian medical news, (133), 111–115.

Disclaimer:
The products mentioned are intended solely for laboratory research and in-vitro experimentation. They are not approved for human or animal use of any kind. All details provided are for educational purposes only. By purchasing from this site, you agree to comply with our Terms and Conditions.